AtriCure, Inc. (ATRC) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $29.16 (+3.74%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 18, 2026 | William Plovanic | Canaccord Genuity | $53.00 | +81.8% |
| Oct 30, 2025 | William Plovanic | Canaccord Genuity | $64.00 | +119.5% |
| Jul 31, 2024 | Rick Wise | Stifel Nicolaus | $26.00 | -10.8% |
| Jul 31, 2024 | Matt O'Brien | Piper Sandler | $40.00 | +37.2% |
| Jul 31, 2024 | Marie Thibault | BTIG | $53.00 | +81.8% |
| May 2, 2024 | Mike Matson | Needham | $40.00 | +37.2% |
| May 2, 2024 | Marie Thibault | BTIG | $58.00 | +98.9% |
| Apr 23, 2024 | Suraj Kalia | Oppenheimer | $32.00 | +9.7% |
| Dec 19, 2022 | Mike Matson | Needham | $58.00 | +98.9% |
| Aug 3, 2022 | Matt O'Brien | Piper Sandler | $55.00 | +88.6% |
Top Analysts Covering ATRC
ATRC vs Sector & Market
| Metric | ATRC | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 6 | 8 | 18 |
| Target Upside | +73.8% | +1150.2% | +14.9% |
| P/E Ratio | -119.31 | 6.98 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $153M | $153M | $154M | 6 |
| 2026-09-30 | $150M | $152M | $153M | 4 |
| 2026-12-31 | $603M | $604M | $605M | 7 |
| 2027-03-31 | $155M | $156M | $158M | 3 |
| 2027-06-30 | $171M | $172M | $174M | 3 |
| 2027-09-30 | $169M | $170M | $172M | 3 |
| 2027-12-31 | $177M | $178M | $180M | 3 |
| 2028-03-31 | $176M | $177M | $179M | 2 |
| 2028-06-30 | $191M | $193M | $195M | 2 |
| 2028-09-30 | $191M | $192M | $194M | 2 |
| 2028-12-31 | $201M | $203M | $205M | 2 |
| 2029-12-31 | $848M | $857M | $863M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.01 | $0.00 | $0.01 | 6 |
| 2026-09-30 | $0.03 | $0.03 | $0.03 | 3 |
| 2026-12-31 | $0.01 | $0.07 | $0.10 | 7 |
| 2027-03-31 | $-0.04 | $-0.04 | $-0.04 | 2 |
| 2027-06-30 | $0.07 | $0.07 | $0.07 | 2 |
| 2027-09-30 | $0.07 | $0.07 | $0.07 | 2 |
| 2027-12-31 | $0.20 | $0.20 | $0.20 | 2 |
| 2028-03-31 | $0.00 | $0.00 | $0.00 | 3 |
| 2028-06-30 | $0.00 | $0.00 | $0.00 | 3 |
| 2028-09-30 | $0.00 | $0.00 | $0.00 | 3 |
| 2028-12-31 | $0.00 | $0.00 | $0.00 | 3 |
| 2029-12-31 | $0.72 | $0.73 | $0.74 | 1 |
Frequently Asked Questions
What is the analyst consensus for ATRC?
The consensus among 6 analysts covering AtriCure, Inc. (ATRC) is Buy with an average price target of $50.67.
What is the highest price target for ATRC?
The highest price target for ATRC is $64.00, set by William Plovanic at Canaccord Genuity on 2025-10-30.
What is the lowest price target for ATRC?
The lowest price target for ATRC is $26.00, set by Rick Wise at Stifel Nicolaus on 2024-07-31.
How many analysts cover ATRC?
6 analysts have issued ratings for AtriCure, Inc. in the past 12 months.
Is ATRC a buy or sell right now?
Based on 6 analyst ratings, ATRC has a consensus rating of Buy (2.00/5) with a +73.8% upside to the consensus target of $50.67.
What are the earnings estimates for ATRC?
Analysts estimate ATRC will report EPS of $0.00 for the period ending 2026-06-30, with revenue estimated at $153M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.